Kalaris Therapeutics, Inc. (KLRS) Stock Profile — Insider Trades & Financials

Net Income-$10.0M

EPS$-2.41

Market Cap$145.4M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Andrew Oxtoby

CEO & Executive Director

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.

Founded: 2019
Employees: 14
Headquarters: Berkeley Heights, New Jersey, United States

⚡

Core Efficiency

ROE?

-12.69%

ROA?

-8.21%

D/E Ratio?

0.54

📊

Profitability Ratios

Current Ratio?

12.23

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 10, 2026 (in 123 days)

Annual Report (10-K) — Based on filing pattern

Aug 10, 2026

Predicted10-K

Mar 17, 2026

10-KQ4 20257d after period end

Mar 17, 2026

10-KFY 202576d after period end

Nov 12, 2025

10-QQ3 20257d after period end

Aug 13, 2025

10-QQ2 20257d after period end

May 14, 2025

10-QQ1 20257d after period end

Mar 7, 2025

10-KQ4 20247d after period end

Mar 7, 2025

10-KFY 202566d after period end

Nov 12, 2024

10-QQ3 20247d after period end

Loading company sections...

Kalaris Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness